MARKET

CLSD

CLSD

Clearside Biomed
NASDAQ
1.200
+0.020
+1.69%
After Hours: 1.200 0 0.00% 16:00 12/02 EST
OPEN
1.160
PREV CLOSE
1.180
HIGH
1.205
LOW
1.160
VOLUME
63.46K
TURNOVER
0
52 WEEK HIGH
3.380
52 WEEK LOW
1.000
MARKET CAP
72.23M
P/E (TTM)
-11.8930
1D
5D
1M
3M
1Y
5Y
Clearside Biomedical Third Quarter 2022 Earnings: Beats Expectations
Clearside Biomedical ( NASDAQ:CLSD ) Third Quarter 2022 Results Key Financial Results Revenue: US$266.0k (down 91% from...
Simply Wall St. · 11/11 10:26
Clearside Biomedical upgraded to buy at Needham on promise for wet AMD candidate
Seekingalpha · 11/10 18:42
Analyst Bumps Up Clearside Biomedical Target Price After Encouraging Trial Data
Benzinga · 11/10 18:24
Stifel Upgrades Clearside Biomedical to Buy, Announces $8 Price Target
Benzinga · 11/10 13:14
Needham Upgrades Clearside Biomedical to Buy, Announces $5 Price Target
Benzinga · 11/10 13:03
HC Wainwright & Co. Maintains Buy on Clearside Biomedical, Raises Price Target to $6
Benzinga · 11/10 11:28
--Needham Upgrades Clearside Biomedical to Buy Rating From Hold, Price Target is $5
--Needham Upgrades Clearside Biomedical to Buy Rating From Hold, Price Target is $5
MT Newswires · 11/10 09:39
--Stifel Upgrades Clearside Biomedical to Buy From Hold, Price Target is $8
--Stifel Upgrades Clearside Biomedical to Buy From Hold, Price Target is $8
MT Newswires · 11/10 08:59
More
About CLSD
Clearside Biomedical, Inc. is a biopharmaceutical company. The Company is focused on developing and delivering therapies to the back of the eye diseases through the suprachoroidal space (SCS). Its SCS injection platform utilizing its SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted delivery of a variety of therapies to the macula, retina or choroid to preserve and improve vision in patients with sight-threatening eye diseases. It is focused on developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector, and it also partners with companies developing other ophthalmic therapeutics to be administered using its SCS injection platform. Its lead product candidate, XIPERE, is a preservative-free suspension of the corticosteroid triamcinolone acetonide (TA), formulated for administration through suprachoroidal injection. Its pipeline includes CLS-AX, CLS-301 and Gene Therapy.

Webull offers kinds of Clearside Biomedical Inc stock information, including NASDAQ:CLSD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CLSD stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CLSD stock methods without spending real money on the virtual paper trading platform.